AXIM Biotechnologies (AXIM) 8-K Axim Biotech Secures Exclusive Licence Agreement to Patented Cannabidiol (CBD) Gum

Exhibit 99.2

AXIM BIOTECHNOLOGEIS, INC.
(Formerly Axim International, Inc.)
Pro Forma Consolidated Balance Sheets
(unaudited)
				December 31, 2014	Pro forma	Reference	Pro Forma
				As reported	Adjustments	No.	Consolidated
ASSETS
Current assets:
	Cash		$	661,128			661,128
	Prepaid expenses			72,329			72,329
	Loan receivable			5,000			5,000
		Total current assets		738,457			738,457
Other Assets:
	Aquired Intangible asset - Intellectual Property Licensing Agreement				5,826,706	(1)	5,826,706
		Total other assets					5,826,706
TOTAL ASSETS			$	738,457			6,565,163
LIABILITIES AND STOCKHOLDERS'  DEFICIT
Current liabilities:
	Accounts payable and accrued liabilities		$	144,385			144,385
	Due to shareholder			5,000			5,000
	Convertible shareholder loan			50,000			50,000
	Due to first insurance funding			54,020			54,020
	Due to related party			65,775			65,775
	Promissory note - related party			1,000,000			1,000,000
		Total current liabilities		1,319,180			1,319,180
STOCKHOLDERS'  DEFICIT
	Preferred stock, $0.0001 par value, 5,000,000 shares authorized;
		1,000,000 issued and outstanding		100			100
	Common stock, $0.0001 par value, 300,000,000 and 195,000,000 shares authorized, respectively;
		38,826,706 issued and outstanding		3,883			3,883
	Additional paid in capital			107,258	5,826,706	(1)	5,933,964
	Accumulated deficit			(691,964)			(691,964)
TOTAL STOCKHOLDERS'  EQUITY (DEFICIT)				(580,723)			5,245,983
TOTAL LIABILITIES AND STOCKHOLDERS'  DEFICIT			$	738,457			6,565,163
(1) To record acqusition of license in exchange for 5,826,706 shares of common stock valued at $1.00 per share